Full-Time

Senior Director

Compound Management, Medicinal Chemistry

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$235k - $281kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • BS/MS or equivalent degree in chemical, biological, engineering sciences or related field with 10+ years working full time in an industrial laboratory setting.
  • Familiarity with modern compound management and modern data systems preferred
  • Proven track record of both compounds and lab management and people leadership across multi-disciplinary drug discovery teams.
  • Managing, coaching and mentoring scientists across the discovery function in order to develop their skills and build RevMed’s organizational capabilities.
  • Innovative team-player with high energy for our fast-paced environment.
  • Strong understanding of chemistry and familiarity with chemistry platforms such as Chemdraw, InstantJChem and Marvin Draw.
  • Demonstrated ability to plan and achieve research goals as part of an interdisciplinary team.
  • Excellent written and verbal communication skills to work with interdepartmental teams.
  • Evidence of successful coaching, mentorship and development of both individuals and teams in order to build long-term organizational capability.
Responsibilities
  • Lead all compound management and Chemistry Lab operation functions including compound registration, inventory, storage, reagent inventory, sample tracking, distribution, communication with collaborators, and sample data management.
  • Establishing strategies that enable growth and expansion of all Compound management, Automation, and Lab management functions.
  • In close collaboration with Discovery Sciences, Biology, and Pharmacology functions enable further optimization of compound management workflows and expanding HTS screening support.
  • Work with external partners to further optimize compound archive and storage, distribution, and inventory management with a view to data safety and company growth.
  • Evaluate and optimize tools that support internal processes and improve user experience. In addition, support changes to software, hardware, and procedures. Proactively seek improvements to usability of these systems and production timelines.
  • Create and maintain SOPs for critical processes.
  • Continue customization of sample software and work closely with vendors to solve problems.
  • Maintain effective oral and written communication to research team members and provide support to ensure timelines are met.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses exclusively on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?